The expanded indication makes risankizumab the first IL-23 inhibitor available for pediatric patients weighing under 40kg with plaque psoriasis or psoriatic arthritis, supported by phase 3 OptIMMize ...

AbbVie today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of children six years of age and older with moderate-to-severe plaque ...

The FDA approved risankizumab-rzaa for children aged at least 6 years with moderate to severe plaque psoriasis who are ...

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval ...

Pharmaceutical maker AbbVie said the Food and Drug Administration approved its Skyrizi to treat pediatric patients with psoriasis. Skyrizi, or risankizumab-rzaa, will be available to patients aged six ...

AbbVie Inc. (NYSE:ABBV) will trade ex-dividend on July 15, putting it among the 10 Best July Dividend Stocks to Buy. On June ...

AbbVie ( ABBV) Tuesday said that the European Commission has approved Skyrizi (risankizumab) for the treatment of children and adolescents six years of age and older with moderate to severe plaque ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved SKYRIZI® (risankizumab) for the treatment of children and adolescents six years of age and older with moderate to ...

European Commission Expands Skyrizi Label to Younger PatientsAbbVie (NYSE:ABBV) has received approval from the European ...

AbbVie has won expanded European Commission approvals for its blockbuster autoimmune drug Skyrizi and its hepatitis C drug Maviret. AbbVie on Tuesday said Skyrizi is now approved in Europe for ...

AbbVie has announced that the European Commission (EC) has approved Skyrizi (risankizumab) for the treatment of children and adolescents six years of age and older with moderate to severe plaque ...

IL-23 inhibitor lands indications for kids 6 years and up ...